Will MSTX Data Be Epic?

Mast Therapeutics Inc. is evaluating its investigational drug Vepoloxamer in a phase III trial in patients with sickle cell disease experiencing vaso-occlusive crisis. Top-line results from this study, dubbed EPIC, are expected to be reported this month. Will the trial live up to its name?

from RTT - Biotech http://ift.tt/2csVc0D
via IFTTT